Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS

NCT04569084 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

384

Enrollment

INDUSTRY

Sponsor class

Stopped Futility was met.

Conditions

ALS

Interventions

DRUG: MT-1186
DRUG: Placebo

Sponsor

Tanabe Pharma America, Inc.